BCLI - ブレインスト―ム・セル・セラピュ―ティクス （Brainstorm Cell Therapeutics Inc.）

Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ETCompany ParticipantsMichael Wood - LifeSci AdvisorsChaim Lebovits - President…

BrainStorm Cell Therapeutics press release (BCLI): Q1 GAAP EPS of -$0.14 beats by $0.03.Cash, cash equivalents, and short-term bank deposits were approximately $2.2M as of March…

Biologics License Application for NurOwn for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, May 15, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading…

Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK,…

Companies Reporting Before The Bell • Caledonia Mining (AMEX: CMCL ) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ: SOHU ) is projected to report earnings for its first quarter. • Modiv (NYSE: MDV ) is estimated to report earnings for its first quarter. • LM Funding America (NASDAQ: LMFA ) is estimated to report quarterly loss at $0.48 per share on revenue of $1.40 million. • Sachem Cap (AMEX: SACH ) is projected to report quarterly earnings at $0.13 per share on revenue of $14.72 million. • Lifeway Foods (NASDAQ: LWAY ) is likely to report quarterly earnings at $0.08 per share on revenue of $36.00 million. • iSun (NASDAQ: ISUN ) is expected to report quarterly loss at $0.20 per share on revenue of $19.78 million. • Carlyle Group (NASDAQ: CG ) is likely to report quarterly loss at $0.09 per share on revenue of $221.89 million. • Azul (NYSE: AZUL ) is projected to report quarterly loss at $0.34 per share on revenue of $932.13 million. • Brainstorm Cell (NASDAQ: BCLI ) is projected to report earnings for its first quarter.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) had its target price hoisted by equities researchers at Maxim Group from $5.00 to $10.00 in a research report issued on Friday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 203.03% […]

Gainers: Y-mAbs Therapeutics YMAB +61%.Burford Capital Limited BUR +42%.Pulse Biosciences PLSE +29%.Brainstorm Cell Therapeutics (BCLI) +29%.Bionomics Limited (BNOX)…

Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsMichael Wood - LifeSci AdvisorsChaim Lebovits -…

Brainstorm Cell Therapeutics (BCLI) stock fell ~10% amid FY22 results after soaring ~50% in the past three days. Read more here

Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting -0.10. At the close of trading, the stock’s price was $3.80, to imply an increase of 12.09% or $0.41 in intraday trading. The BCLI share’s 52-week high remains $4.70, putting it -23.68% down since … Boom Or Bust: What Is Next For Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Stock? Read More »

In Friday’s session, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) marked $3.35 per share, down from $3.40 in the previous session. While Brainstorm Cell Therapeutics Inc. has underperformed by -1.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCLI fell by -5.37%, with highs and lows ranging from […]

Brainstorm is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. Read why I am rating BCLI stock as a buy.

Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q2 2022 Earnings Conference Call August 15, 2022 8:00 A.M.

BrainStorm Cell Therapeutics press release (BCLI): Q2 GAAP EPS of -$0.34.Cash, cash equivalents, and short-term bank deposits were approximately $12.2 million as of June 30,…